Boruzu is the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma, and lowers the ...

The main character 'Gwansik' in the recently popular Netflix drama 'I've been tricked' has died of multiple myeloma, making ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and Shilpa Medicare Limited ("Shilpa") today announced the U.S. launch of BORUZU™, a new ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo regimen of Darzalex, the antibody therapy of Johnson & Johnson (NYSE:JNJ). The ...

Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.

Karnataka: Shilpa Medicare has announced that the Company's marketing partner, Amneal Pharmaceuticals, has launched BORUZU, ...

Hamlet Gasoyan, MD, discusses some of the common challenges that oncologists face when getting patients started on more ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

Multiple myeloma is an incurable blood cancer that ... Administered by subcutaneous injection, it is currently being evaluated in several monotherapy and combination studies.

BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade®, a ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of ...